Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
January 04, 2021 08:55 ET
|
Enzon Pharmaceuticals, Inc
CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the...
Enzon Pharmaceuticals Announces Results of Rights Offering
October 21, 2020 16:15 ET
|
Enzon Pharmaceuticals, Inc
CRANFORD, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced the results of its rights offering following the expiration of the...
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
September 15, 2020 16:15 ET
|
Enzon Pharmaceuticals, Inc
CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
September 02, 2020 16:15 ET
|
Enzon Pharmaceuticals, Inc
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual...
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders
August 21, 2020 16:30 ET
|
Enzon Pharmaceuticals, Inc
CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights...
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value
August 14, 2020 17:00 ET
|
Enzon Pharmaceuticals, Inc
CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits...